Oxybutynin Chloride Tablet, Extended Release
FDA Recall NDC 42291-635

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Oxybutynin Chloride (NDC 42291-635). A significant event, classified as Class III, was initiated on Mar 01, 2019 by Avkare. The reported reason for this action was: "Failed Dissolution Specifications"

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

March 2019 Class III Recall: Failed Dissolution Specifications

Recall Number
Class III Terminated
Reason for Recall
Failed Dissolution Specifications
Initiated
Mar 01, 2019
Reported
Mar 20, 2019
Quantity
a) 2947 and b) 3379

Recall Profile & Regulatory Data

Event ID
82296
Classification
Class III
Enforcement Status
Terminated
Recalling Firm
AVKARE Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide.
Termination Date
Jan 14, 2020
Product Description
Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 42291-634-01) and b) 500 tablets (NDC 42291-634-50) bottles, Rx Only Manufactured for: AvKARE, Inc. Pulaski, TN 38478
Batch or Lot Expiration Information
Lot# Lots: a) 22738 Exp. 07/2020 and b) 22739 Exp. 07/2020
Affected Packages Involved in this Recall
42291-633-01Product
42291-633-50Product
42291-634-01Product
42291-634-50Product
42291-635-01Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.